One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. IFM_05-May 2022
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. One critical finding was an increased risk of
A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. IFM_05-May 2022
The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.
Lenalidomide was the primary drug used for maintenance in this study. Key Findings: